Immunotherapy of Experimental Animal Tumors With Antitumor Antibodies Conjugated to Diphtheria Toxin or Ricin*

Moolten, Frederick L.; Zajdel, S.; Cooperband, S R

doi:10.1111/j.1749-6632.1976.tb41740.x

Cited by 34 publications

(15 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The idea of development of a "magic bullet" that has a specific attraction to a disease-causing target, avoiding healthy body cells, was originally suggested by Paul Ehrlich over 100 years ago [5][6][7]. However, it was only in the 1970s that therapeutic agents composed of toxins conjugated to antibodies against cell surface antigens were shown to kill tumor cells [8,9]. Since then, many hybrid molecules consisting of a toxin coupled with a specific targeting antibody/ligand were developed; most of them are targeted against tumor cells [10] (Figure 1).…”

Section: Ligand Targeted Toxins-immunotoxinsmentioning

confidence: 99%

Toxin-Based Therapeutic Approaches

Shapira

Benhar

2010

Toxins

127

111

View full text Add to dashboard Cite

Protein toxins confer a defense against predation/grazing or a superior pathogenic competence upon the producing organism. Such toxins have been perfected through evolution in poisonous animals/plants and pathogenic bacteria. Over the past five decades, a lot of effort has been invested in studying their mechanism of action, the way they contribute to pathogenicity and in the development of antidotes that neutralize their action. In parallel, many research groups turned to explore the pharmaceutical potential of such toxins when they are used to efficiently impair essential cellular processes and/or damage the integrity of their target cells. The following review summarizes major advances in the field of toxin based therapeutics and offers a comprehensive description of the mode of action of each applied toxin.

show abstract

Section: Ligand Targeted Toxins-immunotoxinsmentioning

confidence: 99%

Toxin-Based Therapeutic Approaches

Shapira

Benhar

2010

Toxins

127

111

View full text Add to dashboard Cite

show abstract

“…Higher potency was expected when polypeptide toxins were coupled to antibodies (Moolten et al 1976). Toxins such as diphtheria toxin have the principal advantage that one molecule, once it has penetrated into the cytoplasm, enzymatically inactivates all ribosomes and thereby induces cell death.…”

Section: B Historical Development •'mentioning

confidence: 99%

“…Toxins such as diphtheria toxin have the principal advantage that one molecule, once it has penetrated into the cytoplasm, enzymatically inactivates all ribosomes and thereby induces cell death. The first antibody-toxin conjugates indeed showed high potency, but only marginal specificity (Moolten et al 1976). The first antibody-toxin conjugates indeed showed high potency, but only marginal specificity (Moolten et al 1976).…”

Section: Introductionmentioning

confidence: 99%

Immunotoxins: Hybrid Molecules Combining High Specificity and Potent Cytotoxicity

Jansen

Blythman

Carrière

et al. 1982

Immunological Reviews

159

View full text Add to dashboard Cite

“…In the 1970s the first therapeutic agents composed of toxins conjugated to antibodies against cell-surface antigens started to emerge as tumor-cell killers (Moolten & Cooperband, 1970), (Moolten et al, 1976). Since then, many hybrid molecules consisting of a toxin coupled to a specific targeting antibody or ligand were developed, with most of these hybrids being directed against tumor cells (Pastan et al, 2007).…”

Section: Immunotoxinsmentioning

confidence: 99%